Payment overview · 2025
General Payments
$2,485.07
141 reported records · 26 companies
Healthcare provider profile · identity verified
Anthony W10 Brown, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CINCINNATI, OH · NPI 1417097361
Verified facts
What the public records show
CMS Open Payments records show Anthony W10 Brown, MD received $2,485.07 in general payments during 2025 across 141 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Nurtec Odt, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $432.39 | 17.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $334.13 | 13.4% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $238.43 | 9.6% | 16 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $184.81 | 7.4% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.48 | 6.1% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $142.94 | 5.8% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $108.02 | 4.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.30 | 3.8% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $93.61 | 3.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.20 | 3.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.25 | 2.5% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $63.13 | 2.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.53 | 2.3% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $53.54 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.39 | 2.1% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $49.22 | 2.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.32 | 1.8% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.39 | 1.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.21 | 1.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.06 | 1.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.09 | 1.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.14 | 0.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.11 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.71 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.71 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.96 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,485.07 | 141 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $402.22 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $314.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $188.23 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $188.23 | 12 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $184.81 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $157.28 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $137.59 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $108.02 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.84 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $100.84 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $93.61 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $91.20 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.07 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.02 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.25 | 4 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $63.13 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $57.53 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $56.07 | 5 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $53.54 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $53.54 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $53.54 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.39 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $49.22 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $48.92 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.34 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.34 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.96 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $44.32 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.39 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.17 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.08 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 147 |
| Lisinopril | Lisinopril | 375 | 100 |
| Montelukast Sodium | Montelukast Sodium | 361 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 67 |
| Metformin Hcl | Metformin Hcl | 212 | 65 |
| Gabapentin | Gabapentin | 186 | 35 |
| Omeprazole | Omeprazole | 182 | 54 |
| Losartan Potassium | Losartan Potassium | 171 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 56 |
| Methylprednisolone | Methylprednisolone | 150 | 102 |
| Alprazolam | Alprazolam | 140 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 68 |
| Famotidine | Famotidine | 130 | 47 |
| Tramadol Hcl | Tramadol Hcl | 127 | 41 |
| Azithromycin | Azithromycin | 126 | 78 |
| Meloxicam | Meloxicam | 126 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 38 |
| Sertraline Hcl | Sertraline Hcl | 123 | 39 |
| Allopurinol | Allopurinol | 120 | 36 |
| Pregabalin | Pregabalin | 119 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 52 |
| Alendronate Sodium | Alendronate Sodium | 107 | 39 |
| Trazodone Hcl | Trazodone Hcl | 105 | 30 |
| Finasteride | Finasteride | 103 | 30 |
| Potassium Chloride | Potassium Chloride | 95 | 29 |
| Clonazepam | Clonazepam | 94 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 62 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 18 |
| Lansoprazole | Lansoprazole | 88 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 26 |
| Diazepam | Diazepam | 77 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 25 |
| Lorazepam | Lorazepam | 75 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 27 |
| Eliquis | Apixaban | 74 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 22 |
| Metformin Hcl Er | Metformin Hcl | 70 | 20 |
| Januvia | Sitagliptin Phosphate | 68 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 31 |
| Torsemide | Torsemide | 61 | 24 |
| Simvastatin | Simvastatin | 60 | 19 |
| Donepezil Hcl | Donepezil Hcl | 57 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 17 |
| Furosemide | Furosemide | 54 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 18 |
| Jardiance | Empagliflozin | 51 | 16 |
| Methocarbamol | Methocarbamol | 49 | 27 |
| Bupropion Xl | Bupropion Hcl | 43 | 15 |
| Carvedilol | Carvedilol | 43 | 15 |
| Farxiga | Dapagliflozin Propanediol | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 31 |
| Nitroglycerin | Nitroglycerin | 37 | 14 |
| Prednisone | Prednisone | 37 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 19 |
| Mupirocin | Mupirocin | 34 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Ozempic | Semaglutide | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Acarbose | Acarbose | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 14 |
| Risperidone | Risperidone | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Valsartan | Valsartan | 24 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 23 | 13 |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 15 |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clarithromycin | Clarithromycin | 13 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tradjenta | Linagliptin | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,485.07 · 141 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, Grastek, JARDIANCE, JOURNAVX, KISUNLA, LEQVIO, LOREEV XR, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Odactra, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Ragwitek, Rybelsus, TERIPARATIDE, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Veozah, WATCHMAN Access System, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error